Clinical Trial

A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate if the addition of SCTC21C to bortezomib, lenalidomide and dexamethasone (VRd) in patients with newly diagnosed multiple myeloma not eligible for transplant will prolong progression-free survival (PFS) and/or improve overall minimal residual disease (MRD) negativity rate compared with VRd alone.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-12-16.
Status change: Not Yet Recruiting → Recruiting 2026-01-28
Trial Details
NCT Number NCT07297329
Lead Sponsor Sinocelltech Ltd.
Conditions Multiple Myeloma (MM)
Enrollment 292 participants
Start Date 2025-12-29
Primary Completion 2027-12 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-01-29